Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus


CEO Martin Vidaeus of Redwood Pharma updates industry and shareholders of the status of the RP101 Phase II trial at the Bio-Stock forum on December 3, 2019 in Stockholm, Sweden.


About RP101
RP101 is a novel, topical treatment for post-menopausal women suffering from chronic, moderate-to-severe dry eye disease (DED), and consists of a low-dose estrogen analog formulated in a proprietary controlled-release drug delivery platform, IntelliGel. The active substance has already been proven safe and efficacious in two Phase II clinical trials conducted in the US. Redwood Pharma is currently conducting a Phase II clinical trial of RP101 in Europe, with topline results expected during Q1 2020.

DED is the number one reason patients visit eye doctors, and this condition represents a large and growing market. Approximately 100 million suffer from chronic DED, and the global market for pharmaceuticals treating DED was valued at US$3bn in 2018. There is an urgent need for new, more effective therapies, and RP101 is positioned to be the first hormonal therapy for post-menopausal women. An estimated 7% of post-menopausal women – 10 million in the US and Europe alone – suffer from severe DED. Where conventional therapies only treat symptoms of the disease, RP101 addresses the underlying cause of the discomfort by targeting and restoring the production of critical components of the natural tear film.


For more information please contact:

Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29


About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on Spotlight Stock Market (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: